Cargando…
克唑替尼治疗晚期NSCLC患者单中心回顾性分析
BACKGROUND AND OBJECTIVE: Crizotinib was developed in recent years based on targets of anaplastic lymphoma kinase (ALK) fusion genes. The aim of this study is to explore the efficacy of crizotinib in treatment of non-small cell lung cancer (NSCLC) with ALK/ROS1 rearrangement. METHODS: Retrospective...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999819/ https://www.ncbi.nlm.nih.gov/pubmed/27009821 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.03.07 |